PerkinElmer, Inc. (PKI) Shares Bought by Bank of New York Mellon Corp
Bank of New York Mellon Corp boosted its stake in shares of PerkinElmer, Inc. (NYSE:PKI) by 8.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,007,210 shares of the medical research company’s stock after buying an additional 74,735 shares during the period. Bank of New York Mellon Corp’s holdings in PerkinElmer were worth $73,647,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in PKI. American Century Companies Inc. acquired a new stake in PerkinElmer during the 4th quarter worth approximately $61,260,000. Robecosam AG raised its holdings in shares of PerkinElmer by 165.7% in the third quarter. Robecosam AG now owns 477,167 shares of the medical research company’s stock valued at $32,610,000 after purchasing an additional 297,595 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of PerkinElmer by 135.0% in the third quarter. Russell Investments Group Ltd. now owns 250,350 shares of the medical research company’s stock valued at $17,268,000 after purchasing an additional 143,822 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of PerkinElmer by 555,238.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 116,621 shares of the medical research company’s stock valued at $8,527,000 after purchasing an additional 116,600 shares during the last quarter. Finally, Icon Advisers Inc. Co. acquired a new stake in shares of PerkinElmer in the fourth quarter valued at approximately $7,654,000. Hedge funds and other institutional investors own 90.06% of the company’s stock.
A number of analysts have recently issued reports on PKI shares. Evercore ISI started coverage on shares of PerkinElmer in a report on Wednesday, January 3rd. They issued an “in-line” rating and a $77.00 price objective on the stock. Robert W. Baird reiterated a “buy” rating and issued a $88.00 price objective on shares of PerkinElmer in a report on Friday, January 26th. Cowen reiterated a “hold” rating and issued a $84.00 price objective on shares of PerkinElmer in a report on Friday, January 26th. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Monday, January 8th. Finally, ValuEngine downgraded shares of PerkinElmer from a “buy” rating to a “hold” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $76.85.
PerkinElmer, Inc. (NYSE:PKI) opened at $74.73 on Friday. The firm has a market cap of $8,240.00, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.72 and a beta of 0.79. PerkinElmer, Inc. has a fifty-two week low of $53.97 and a fifty-two week high of $84.49. The company has a current ratio of 1.26, a quick ratio of 0.90 and a debt-to-equity ratio of 0.71.
PerkinElmer (NYSE:PKI) last issued its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.94 by $0.03. The business had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The firm’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.83 earnings per share. analysts anticipate that PerkinElmer, Inc. will post 3.52 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be issued a dividend of $0.07 per share. The ex-dividend date is Thursday, April 12th. This represents a $0.28 dividend on an annualized basis and a yield of 0.37%. PerkinElmer’s payout ratio is 11.76%.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/03/04/perkinelmer-inc-pki-shares-bought-by-bank-of-new-york-mellon-corp.html.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.